Knight Therapeutics - KHTRF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 80.29%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.16
▼ -0.11 (-2.58%)

This chart shows the closing price for KHTRF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Knight Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KHTRF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KHTRF

Analyst Price Target is $7.50
▲ +80.29% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Knight Therapeutics in the last 3 months. The average price target is $7.50, with a high forecast of $7.50 and a low forecast of $7.50. The average price target represents a 80.29% upside from the last price of $4.16.

This chart shows the closing price for KHTRF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Knight Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/6/2024Raymond JamesBoost TargetOutperform ➝ Outperform$7.00 ➝ $7.50
8/15/2022Stifel NicolausBoost TargetC$5.30 ➝ C$5.40
5/13/2022Knight EquityLower TargetC$7.00 ➝ C$6.75
3/25/2022Raymond JamesLower TargetC$8.50 ➝ C$7.50
3/25/2022Knight EquityLower TargetC$8.00 ➝ C$7.00
3/25/2022Stifel NicolausDowngradeBuy ➝ HoldC$7.00 ➝ C$5.30
11/15/2021Stifel NicolausBoost TargetBuyC$6.50 ➝ C$7.00
9/23/2021Stifel EuropeUpgradeHold ➝ BuyC$5.95 ➝ C$6.50
4/26/2021KCGBoost TargetOutperform$6.75 ➝ $7.75
4/26/2021Cannonball ResearchReiterated RatingBuy
4/26/2021Raymond JamesReiterated RatingOutperform
4/26/2021Knight EquityBoost TargetOutperform$6.75 ➝ $7.75
11/16/2020KCGLower TargetOutperform$8.25 ➝ $6.75
11/16/2020Knight EquityLower TargetOutperform$8.25 ➝ $6.75
8/13/2020Stifel NicolausInitiated CoverageBuy$10.50
6/23/2020Stifel NicolausReiterated RatingBuy$10.50
10/9/2019Raymond JamesSet TargetBuy$10.30
(Data available from 6/24/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Knight Therapeutics logo
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Read More

Today's Range

Now: $4.16
Low: $4.14
High: $4.16

50 Day Range

MA: $4.28
Low: $4.16
High: $4.41

52 Week Range

Now: $4.16
Low: $3.20
High: $4.41

Volume

900 shs

Average Volume

6,290 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Knight Therapeutics?

The following equities research analysts have issued reports on Knight Therapeutics in the last twelve months: Raymond James.
View the latest analyst ratings for KHTRF.

What is the current price target for Knight Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Knight Therapeutics in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 80.3%. Raymond James has the highest price target set, predicting KHTRF will reach $7.50 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $7.50 for Knight Therapeutics in the next year.
View the latest price targets for KHTRF.

What is the current consensus analyst rating for Knight Therapeutics?

Knight Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KHTRF will outperform the market and that investors should add to their positions of Knight Therapeutics.
View the latest ratings for KHTRF.

What other companies compete with Knight Therapeutics?

How do I contact Knight Therapeutics' investor relations team?

Knight Therapeutics' physical mailing address is 3400 de Maisonneuve West, Montréal, QC H3Z. The company's listed phone number is (514) 484-4483. The official website for Knight Therapeutics is www.gud-knight.com. Learn More about contacing Knight Therapeutics investor relations.